Laboratory Products

  • Labelling Solution Offers an Instant Validated Platform for COVID-19 Clinical Trials   
  • Warren Stacey, PRISYM ID.

Labelling Solution Offers an Instant Validated Platform for COVID-19 Clinical Trials   

Apr 08 2020 Read 2365 Times

PRISYM ID, a leading provider of data-led label and artwork management solutions today announced its PRISYM 360 SaaS clinical trials labelling solution is live with customers and available to those pharmaceutical and trials organisations who need quick entry to clinical label printing.

To support the life sciences sector’s response to Covid-19, PRISYM ID is offering a cloud-based, ready to use version of its clinical trials SaaS labelling platform including a pre-validated pack with industry standard print processes.  It is fast to onboard, needs minimal IT input to set up and provides certainty to the market in these uncharted times.

Being pre-validated, the application removes a significant proportion of the cost, time and risk associated with implementing and validating a labelling system. It provides organisations with the control and agility needed to remove risk for clinical trial printing processes.

Key features of this version include: role based security controls; printer agnostic label designs; clinical trial filtered study and sequenced printing (Clinical Trial Supply); product label printing; comprehensive, secure audit log including the ability to transfer content and templates to different organisations as the trial grows; language management controls; version and state control of all design and content elements; version and state control of data models and workflows; workflow templates; clinical trial data management, including the import and management of randomised data; extensive barcode symbology support, including GS1 Clinical Trials; hosted through a fully validated and compliant cloud environment.

Warren Stacey, SVP of Sales at PRISYM ID, commented: “With the life science industry working at exceptional speed to run trials and accelerate the speed at which they come to market, labelling may be something of an afterthought. Yet it is critical to the process. Generic labelling software may be a blunt tool when it comes to validation, version control, compliance and navigating the nuances of the clinical trials supply chain. Our PRISYM 360 SaaS solution already has customers live in this space and it offers clinical researchers an off-the-shelf platform that’s fit for purpose, validated and secure.”

Warren continued: “To help the cause, we are offering organisations who are responding to Covid-19 special provisions to speed up their ability to get access to the solution, with environments being set up in advance and a team waiting to onboard them. A process that may normally take months has been reduced to days.”  

More information online 

 


Digital Edition

International Labmate March 2021

March 2021

In This Edition Articles - dia-PASEF: A Result of the Co-evolution of Mass Spectrometry and Proteomics - Soft-Condensed Matter Science has a bright future via the Diamond-II upgrade Chrom...

View all digital editions

Events

PITTCON 2021

Mar 08 2021 Virtual Event

Bio-Europe Spring

Mar 22 2021 Digital event

Medtec Japan 2021

Apr 14 2021 Tokyo, Japan

MedtecLIVE

Apr 20 2021 Virtual event

ChemBio Finland - Virtual preview

Apr 28 2021 Virtual event

View all events